GCA Altium advises Arcline on its acquisition of ChargePoint
ChargePoint is headquartered in Liverpool, UK. Its products are used primarily in pharmaceutical manufacturing and bioprocessing applications and include multi-use and single-use split butterfly valves, charge bottles and bags, process solution accessories, and spare parts. These mission-critical technologies enable ChargePoint’s customers, including all the top 20 global pharmaceutical companies, to establish safe and reliable manufacturing process environments.
The transaction is the inaugural investment of Arcline’s second fund and marks an exit for LDC following a four-year partnership with ChargePoint. ChargePoint is anticipated to be the first of several acquisitions as Arcline builds a specialty process technologies platform focused on pharmaceutical and biopharmaceutical end markets.
Chris Eccles, CEO of ChargePoint, said: “We are excited to partner with Arcline, a firm that shares our passion for providing our customers with safer containment and sterile transfer technologies, which are critical to the future of medicine. We look forward to expanding our critical role in pharmaceutical manufacturing and bioprocessing as we invest in our next phase of growth.”
Adam Sivner, Director at GCA Altium, commented: “We are delighted to have advised Arcline on the acquisition of ChargePoint. This is the second time GCA Altium has advised on the acquisition of the business, having previously advised LDC in 2016. ChargePoint is a world leader in containment solutions for the pharma and biopharma sectors and they have found an excellent partner in Arcline. Utilising the private equity relationships of our US offices, this transaction is indicative of the power of GCA Altium’s global platform.”